These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11872048)

  • 1. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.
    Leonard DS; Hill AD; Kelly L; Dijkstra B; McDermott E; O'Higgins NJ
    Br J Surg; 2002 Mar; 89(3):262-71. PubMed ID: 11872048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing and planned adjuvant trials with trastuzumab.
    Perez EA; Hortobagyi GN
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
    Fornier M; Esteva FJ; Seidman AD
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
    Burris HA
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
    Pegram MD; Slamon DJ
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):89-95. PubMed ID: 10482199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and planned clinical trials with trastuzumab (Herceptin).
    Baselga J
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rationale for Herceptin in the clinical use].
    Ebi H; Sasaki Y
    Nihon Rinsho; 2002 Mar; 60(3):463-7. PubMed ID: 11904959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y
    Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials of single-agent trastuzumab (Herceptin).
    Baselga J
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):20-6. PubMed ID: 11049053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of Herceptin(trastuzumab).
    Baselga J
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S18-24. PubMed ID: 11167087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.